Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide Combined With Obinutuzumab in Relapsed/Refractory Indolent Lymphoma
NCT07441954Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Molecular Glues
01
Overview
A Phase 2 trial of pomalidomide in lymphoma, sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
pomalidomide
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT07441954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07441954.